Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 10/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23882906 | 1.00 | MRGPRX4 (0.43) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23905923 | 1.00 | MRGPRX4 (0.43) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL30251402 | 1.00 | MRGPRX4 (0.43) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23905979 | 0.92 | MRGPRX4 (0.38) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL32675565 | 0.92 | MRGPRX4 (0.38) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23882773 | 0.92 | MRGPRX4 (0.38) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23905936 | 0.92 | MRGPRX4 (0.40) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23882834 | 0.92 | MRGPRX4 (0.40) | MRGPRX4SRD5A2LTB4RLTB4R2GRM5 | |
| SCHEMBL23882832 | 0.91 | GRM5 (0.40) | MRGPRX4LTB4RLTB4R2GRM5 | |
| SCHEMBL30251154 | 0.91 | GRM5 (0.40) | MRGPRX4LTB4RLTB4R2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | MRGPRX4 124/4885SRD5A2 1443/4885LTB4R 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.